England's oldest Test cricketer, Raman Subba Row, dies aged 92
Raman Subba Row’s cricketing journey began at Cambridge University before he joined the dominant Surrey team of the 1950s, which captured seven consecutive County Championships.
Vivek Mishra works as an Assistant Editor with Eastern Eye and has over 13 years of experience in journalism. His areas of interest include politics, international affairs, current events, and sports. With a background in newsroom operations and editorial planning, he has reported and edited stories on major national and global developments.
RAMAN Subba Row, former England Test batsman, passed away at the age of 92, announced by the England and Wales Cricket Board (ECB) on Thursday.
At his passing, he held the distinction of being the oldest living men's Test cricketer from England.
Subba Row's cricketing journey began at Cambridge University before he joined the dominant Surrey team of the 1950s, which captured seven consecutive County Championships.
He later transferred to Northamptonshire and was named captain in 1958.
That same year marked the beginning of Subba Row's international career with England, earning his first of 13 caps.
Notably, in 1961, he achieved centuries in both his debut and final Test matches against Australia. Throughout his Test career, he amassed 984 runs at an impressive average of over 46.
Following his retirement from playing, he shifted to a business career and managed the England cricket team during their 1981 tour of India and Sri Lanka.
Subba Row also played a significant role in cricket administration, serving as chairman of the Test and County Cricket Board (the predecessor to the ECB) for five years starting in 1985 and later became one of the first match referees for the International Cricket Council (ICC), overseeing 160 fixtures.
Wasim Khan, ICC general manager of cricket, expressed his condolences, stating, "It is sad to hear of the passing of Raman and I would like to extend deepest condolences on behalf of everyone at the ICC. Raman was a respected cricketer of his era, who went on to become the chair of the Test and County Cricket Board. He was also one of the earliest ICC match referees, officiating very ably in different parts of the world."
ECB chairman Richard Thompson also reflected on Subba Row's vast contributions, saying, "We are extremely saddened to hear of Raman's passing. He was a great cricket man and his remarkable cricket career saw success both on and off the field -- as a player, official, administrator and chair of both Surrey and the Test and County Cricket Board."
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.